

Cancer

**Study Evaluating the Safety, Pharmacokinetics (PK),  
Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab  
(RO7009789) With Vanucizumab or Bevacizumab in Participants  
With Metastatic Solid Tumors**

**Trial Status**  
Completed

**Trial Runs In**  
7 Countries

**Trial Identifier**  
NCT02665416 2015-003480-11  
BP29889

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of Selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to standard treatment. Part I (dose escalation) is designed to establish the maximum tolerated dose (MTD) of Selicrelumab in this combination. Part II (expansion) is intended to characterize the safety and tolerability of Selicrelumab in combination with bevacizumab among indication-specific cohorts and to confirm the recommended dose.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT02665416 2015-003480-11 BP29889**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years

**Healthy Volunteers**  
No

---